Fujitsu's Biosciences Group this week launched a new version of its automated microinjection technology that will allow users to transfect adherent cells without having to first trypsinize them to release them from their growth surface.

The new platform, which Fujitsu says nearly doubles the transformation efficiency in difficult-to-transfect cell types, could allow Fujitsu to better compete with vendors such as Cellectricon and Cyntellect that have already developed alternative high-throughput transfection methods for such cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.